Merck & Co.

Global Anti-Infective Drugs Market Report 2021: COVID-19 Implications and Growth to 2030 - ResearchAndMarkets.com

Thursday, September 23, 2021 - 10:07am

The "Anti-Infective Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-Infective Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Anti-Infective Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.
  • The global anti-infective drugs market is expected to decline from $132.16 billion in 2020 to $116.4 billion in 2021 at a compound annual growth rate (CAGR) of -11.9%.
  • North America was the largest region in the global anti-infective drugs market, accounting for 50% of the market in 2020.

PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Wednesday, September 22, 2021 - 1:30pm

FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.

Key Points: 
  • FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.
  • The conference is taking place virtually from September 27 - 30, 2021.
  • Details for the presentation are as follows:
    Cantor Fitzgerald Virtual Global Healthcare Conference:
    Following the conference a webcast replay of the presentation will be available on the Investor section of the companys website, PDS Biotechnology .
  • PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform.

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Wednesday, September 22, 2021 - 11:30am

In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.

Key Points: 
  • In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.
  • Matthias Dobbelstein, M.D., Professor of Molecular Oncology, University Medical Center Goettingen, added, "We are proud of the results of our preclinical work.
  • We were very pleased with this license agreement with Immunic and look forward to future results with these very promising combinations."
  • Although the technology in-licensed by Immunic includes the potential combination of DHODH inhibitors with nucleoside analogues, including molnupiravir, Immunic does not have any rights to molnupiravir itself.

DGAP-News: Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Wednesday, September 22, 2021 - 11:59am

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19- Preclinical Combination Data Suggests Extra-Ordinary Synergy Between Certain DHODH Inhibitors and Nucleoside Analogues -- Combination of IMU-838 and N4-Hydroxycytidine Reduced SARS-CoV-2 Virus Levels, Including the Delta Variant, Down to the Detection Limit -NEW YORK and GOETTINGEN, Germany, September 22, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the execution of an in-license agreement with the University Medical Center Goettingen, Germany, covering the combination of DHODH inhibitors and nucleoside analogues to treat viral infections (COVID-19 and Influenza). Terms of the agreement were not disclosed.
Preclinical research recently completed by the parties and their collaborators[1] has shown that certain DHODH inhibitors, including Immunic's lead asset, IMU-838, strongly synergize with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro. For instance, in an in vitro test system, IMU-838 alone showed an up to 99.9% reduction in viral RNA at concentrations of 5 μM, which is well within the exposure levels seen in prior clinical trials. Likewise, N4-hydroxycytidine (NHC), the active metabolite of molnupiravir[2], alone, was associated with an up to 99% reduction in viral RNA at concentrations of 100 nM. Compared to single agent activity, the combination of IMU-838 and NHC achieved an extra-ordinary reduction in viral RNA, down to the limit of detection, reducing SARS-CoV-2 RNA by up to seven log units (corresponding to 0.00001% viral RNA remaining). This powerful reduction of virus replication in vitro was demonstrated across multiple SARS-CoV-2 variants, including alpha, beta and delta, highlighting the independence of this approach to mutant virus forms. In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro. The company plans to present detailed data at an upcoming scientific conference.
"Research by the University Medical Center Goettingen and other research partners revealed a profound degree of synergy in vitro when combining certain nucleoside analogues with DHODH inhibitors, including both our lead asset IMU-838 and other of our preclinical molecules," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "Recalling IMU-838's clinical activity against COVID-19 in our phase 2 CALVID-1 trial published earlier this year, and in light of recent exacerbations in COVID-19, worldwide, we are very excited to have in-licensed this technology to incorporate into our pandemic preparedness effort. However, with the extra-ordinary wealth of activity already ongoing at the company in other programs, we intend to evaluate and pursue the best possible strategic option for this program, including potential partnership, collaboration or external funding."

Key Points: 
  • Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
    The issuer is solely responsible for the content of this announcement.
  • In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.
  • Matthias Dobbelstein, M.D., Professor of Molecular Oncology, University Medical Center Goettingen, added, "We are proud of the results of our preclinical work.
  • Although the technology in-licensed by Immunic includes the potential combination of DHODH inhibitors with nucleoside analogues, including molnupiravir, Immunic does not have any rights to molnupiravir itself.

BioNJ's Ninth Annual C-Suite Summit: Transitioning to the 'Next Normal'

Tuesday, September 21, 2021 - 2:00pm

Following safety guidelines, including requiring on-site proof of vaccination (masking is recommended), attendees will enjoy networking, cocktails,dinner foodand first-hand views of the beautifully manicured fairways of the Club's golf course and 260 private acres.

Key Points: 
  • Following safety guidelines, including requiring on-site proof of vaccination (masking is recommended), attendees will enjoy networking, cocktails,dinner foodand first-hand views of the beautifully manicured fairways of the Club's golf course and 260 private acres.
  • "Therefore, this year's program is dedicated to taking a look at the 'Next Normal'.
  • Click here to register.Now a lower cost:Registration is $350 for Members and $450 for future BioNJ Members.
  • The registration fee includes the Networking Reception on Thursday, October 14, 2021, as well as the full-day virtual event on Friday, October 15, 2021.

BlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board

Tuesday, September 21, 2021 - 12:00pm

BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.

Key Points: 
  • BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.
  • The members of the BlueWillow Biologics SAB include:
    Robin Isaacs, M.D.
  • Prior, he held positions of increasing responsibility at Merck & Co., Inc., most recently serving as Vice President and Therapeutic Area Head, Vaccine Clinical Research.
  • We are proud to have such a distinguished team of scientific experts serve as members of our Scientific Advisory Board, underscoring their belief in our intranasal vaccines to elicit mucosal immunity, commented Chad Costley, M.D., President and Chief Executive Officer of BlueWillow Biologics.

Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Markets 2020-2021 & 2026: Focus on Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others - ResearchAndMarkets.com

Monday, September 20, 2021 - 4:10pm

The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.

Key Points: 
  • The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.
  • However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs challenge the growth of the market.
  • The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type.
  • Geographically, the global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

Hepatitis Therapeutics Markets: Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others - Global Forecast to 2027 - ResearchAndMarkets.com

Monday, September 20, 2021 - 2:26pm

The "Hepatitis Therapeutics Market, By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Other Types), Drug Class (Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others) and Region: Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepatitis Therapeutics Market, By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Other Types), Drug Class (Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others) and Region: Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Hepatitis Therapeutics market size is estimated to grow at a CAGR of 3.5% during the forecast year from 2021 to 2027.
  • The latest report on Hepatitis Therapeutics Market understands market size estimates, forecasts, market shares, competition analysis, along with industry trends of Hepatitis Therapeutics with emphasis on market timelines and technology roadmaps analysis.
  • The Hepatitis Therapeutics market is segmented by disease type, drug class and region.

PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer

Monday, September 20, 2021 - 1:30pm

The trial is being conducted in collaboration with Merck & Co.

Key Points: 
  • The trial is being conducted in collaboration with Merck & Co.
    VERSATILE-002 is studying two groups of HPV16-positive head and neck cancer patients whose cancer has returned or spread.
  • The achievement of this important milestone in the VERSATILE-002 Phase 2 clinical trial strengthens the evidence regarding the safety of PDS0101.
  • There is an enormous unmet medical need for more effective treatment of advanced head and neck cancer.
  • That trial has enrolled patients with anal, cervical, head and neck, vaginal and vulvar cancer, who have failed prior treatment.

MerckManuals.com Offers Key Takeaways on What We Have Learned about Telemedicine from the Pandemic

Monday, September 20, 2021 - 1:45pm

A recurring point made in the expanded essay is that with all healthcare visits, preparation is critical to making them productive.

Key Points: 
  • A recurring point made in the expanded essay is that with all healthcare visits, preparation is critical to making them productive.
  • "The rise of telehealth has transformed the healthcare arena," said Michael R. Wasserman, M.D., Merck Manuals editorial board member and contributor of the new content related to telemedicine.
  • "While there may be no substitute for an in-person office visit with a clinician, telemedicine clearly serves as a beneficial supplement to traditional patient care."
  • Takeaways about what the pandemic has taught us about telemedicine follow.